PedAM
Pediatric Disease Annotations & Medicines
| glomerulonephritis | ||||
| Disease ID | 271 |
|---|---|
| Disease | glomerulonephritis |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:79) C2697310 | sarcoidosis C2364133 | infection C1963274 | vasculitis C1963154 | renal failure C1963138 | hypertension C1962972 | proteinuria C1881236 | interstitial disease C1839611 | n syndrome C1827745 | disseminated mycobacterium gordonae infection C1579029 | chronic uremia C1565489 | renal insufficiency C1417247 | glomerulosclerosis C1373218 | immunosuppression C0948347 | nephroangiosclerosis C0948265 | metabolic syndrome C0748159 | pulmonary involvement C0746556 | metabolic disturbance C0730345 | microalbuminuria C0728936 | circulatory disorders C0426359 | urinary symptoms C0403447 | chronic renal insufficiency C0403447 | chronic renal disease C0343208 | essential mixed cryoglobulinemia C0334054 | cystic disease C0265050 | vena cava thrombosis C0235989 | renal interstitial fibrosis C0206061 | interstitial pneumonitis C0178664 | glomerular sclerosis C0162538 | selective iga deficiency C0155862 | pneumococcal pneumonia C0155616 | secondary hypertension C0154251 | lipid metabolism disorders C0151620 | hypertensive encephalopathy C0149746 | orthostasis C0086981 | sicca syndrome C0042384 | vasculitides C0041349 | tubulointerstitial nephritis C0040188 | tic disorders C0039263 | takayasu's arteritis C0038395 | streptococcal infection C0037140 | b virus infection C0036416 | scleritis C0034186 | pyelonephritis C0034150 | purpura C0034063 | pulmonary edema C0033117 | priapism C0032962 | pregnancy complications C0032285 | pneumonia C0032227 | pleural effusions C0027726 | nephrotic syndromes C0027726 | nephrotic syndrome C0027707 | interstitial nephritis C0025517 | metabolic disorders C0025517 | metabolic disorder C0024141 | systemic lupus erythematosus C0022661 | end-stage renal disease C0022661 | chronic renal failure C0022661 | chronic kidney failure C0022660 | acute renal failure C0022660 | acute kidney failure C0022658 | renal disease C0022521 | kartagener syndrome C0021053 | immune disorders C0020807 | pulmonary hemosiderosis C0020639 | hypoproteinaemia C0020538 | systemic hypertension C0020488 | sodium retention C0019163 | hepatitis b infection C0019158 | hepatitis C0019080 | hemorrhage C0014378 | enterovirus infections C0014118 | endocarditis C0010403 | cryoglobulinemia C0010403 | cryoglobulinaemia C0007134 | renal adenocarcinoma C0005940 | bone diseases C0005779 | blood coagulation disorders C0004364 | autoimmune disease C0004153 | atherosclerosis |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:33) C0035078 | renal failure | 37 C0033687 | proteinuria | 22 C0022658 | renal disease | 21 C0009450 | infection | 20 C0027726 | nephrotic syndrome | 20 C0022661 | end-stage renal disease | 16 C0019158 | hepatitis | 13 C0022661 | chronic renal failure | 12 C0024141 | systemic lupus erythematosus | 12 C0042384 | vasculitis | 9 C0019080 | hemorrhage | 7 C0027707 | interstitial nephritis | 7 C0010403 | cryoglobulinemia | 7 C0178664 | glomerulosclerosis | 6 C0014118 | endocarditis | 5 C0022660 | acute renal failure | 5 C0038395 | streptococcal infection | 4 C0004364 | autoimmune disease | 4 C0020538 | hypertension | 3 C0021079 | immunosuppression | 3 C0041349 | tubulointerstitial nephritis | 3 C0034150 | purpura | 2 C0032285 | pneumonia | 2 C0010403 | cryoglobulinaemia | 2 C0403447 | chronic renal insufficiency | 1 C1565489 | renal insufficiency | 1 C0019163 | hepatitis b infection | 1 C0022661 | chronic kidney failure | 1 C0036202 | sarcoidosis | 1 C0155862 | pneumococcal pneumonia | 1 C0042384 | vasculitides | 1 C1839611 | n syndrome | 1 C0343208 | essential mixed cryoglobulinemia | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:3) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1045642 | 22380717 | 5243 | ABCB1 | umls:C0017658 | BeFree | The CYP2B6*9 and ABCB1 C3435T polymorphisms alter the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in glomerulonephritis. | 0.000271442 | 2012 | ABCB1 | 7 | 87509329 | A | T,G |
| rs1045642 | 22380717 | 1555 | CYP2B6 | umls:C0017658 | BeFree | The CYP2B6*9 and ABCB1 C3435T polymorphisms alter the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in glomerulonephritis. | 0.000271442 | 2012 | ABCB1 | 7 | 87509329 | A | T,G |
| rs1570360 | 24673399 | 7422 | VEGFA | umls:C0017658 | BeFree | The association between therapeutic outcomes and VEGF G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis. | 0.001628651 | 2015 | VEGFA | 6 | 43770093 | A | G |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:36) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0017658 | ampicillin | D000667 | 69-53-4 | glomerulonephritis | MESH:D005921 | marker/mechanism | 6236237 | ||
| C0017658 | benazepril | C044946 | 86541-75-5 | glomerulonephritis | MESH:D005921 | therapeutic | 15315341 | ||
| C0017658 | carbimazole | D002231 | 22232-54-8 | glomerulonephritis | MESH:D005921 | marker/mechanism | 15785249 | ||
| C0017658 | ciprofloxacin | D002939 | 85721-33-1 | glomerulonephritis | MESH:D005921 | marker/mechanism | 8213803 | ||
| C0017658 | cyclophosphamide | D003520 | 50-18-0 | glomerulonephritis | MESH:D005921 | marker/mechanism | 17686619 | ||
| C0017658 | cyclophosphamide | D003520 | 50-18-0 | glomerulonephritis | MESH:D005921 | therapeutic | 11805173 | ||
| C0017658 | cisplatin | D002945 | 15663-27-1 | glomerulonephritis | MESH:D005921 | marker/mechanism | 812603 | ||
| C0017658 | diclofenac | D004008 | 15307-86-5 | glomerulonephritis | MESH:D005921 | marker/mechanism | 8882757 | ||
| C0017658 | calcitriol | D002117 | 32222-06-3 | glomerulonephritis | MESH:D005921 | therapeutic | 9607202 | ||
| C0017658 | enalapril | D004656 | 75847-73-3 | glomerulonephritis | MESH:D005921 | marker/mechanism | 3027632 | ||
| C0017658 | enalapril | D004656 | 75847-73-3 | glomerulonephritis | MESH:D005921 | therapeutic | 15496148 | ||
| C0017658 | everolimus | D000068338 | - | glomerulonephritis | MESH:D005921 | marker/mechanism | 16302997 | ||
| C0017658 | foscarnet | D017245 | 4428-95-9 | glomerulonephritis | MESH:D005921 | marker/mechanism | 10360595 | ||
| C0017658 | imatinib mesylate | D000068877 | - | glomerulonephritis | MESH:D005921 | therapeutic | 19242505 | ||
| C0017658 | indomethacin | D007213 | 53-86-1 | glomerulonephritis | MESH:D005921 | marker/mechanism | 4106997 | ||
| C0017658 | indomethacin | D007213 | 53-86-1 | glomerulonephritis | MESH:D005921 | therapeutic | 860058 | ||
| C0017658 | mebendazole | D008463 | 31431-39-7 | glomerulonephritis | MESH:D005921 | marker/mechanism | 7173081 | ||
| C0017658 | mephenytoin | D008617 | 1950/12/4 | glomerulonephritis | MESH:D005921 | marker/mechanism | 1246508 | ||
| C0017658 | nicotine | D009538 | - | glomerulonephritis | MESH:D005921 | marker/mechanism | 20685820 | ||
| C0017658 | norepinephrine | D009638 | 51-41-2 | glomerulonephritis | MESH:D005921 | marker/mechanism | 11459117 | ||
| C0017658 | oxycodone | D010098 | 76-42-6 | glomerulonephritis | MESH:D005921 | marker/mechanism | 12203209 | ||
| C0017658 | pamidronate | C019248 | 40391-99-9 | glomerulonephritis | MESH:D005921 | marker/mechanism | 14964460 | ||
| C0017658 | phenindione | D010630 | 1983/12/5 | glomerulonephritis | MESH:D005921 | marker/mechanism | 228409 | ||
| C0017658 | phentermine | D010645 | 122-09-8 | glomerulonephritis | MESH:D005921 | marker/mechanism | 10435891 | ||
| C0017658 | phenytoin | D010672 | 57-41-0 | glomerulonephritis | MESH:D005921 | marker/mechanism | 19644425 | ||
| C0017658 | pirfenidone | C093844 | 53179-13-8 | glomerulonephritis | MESH:D005921 | therapeutic | 15561744 | ||
| C0017658 | piroxicam | D010894 | 36322-90-4 | glomerulonephritis | MESH:D005921 | marker/mechanism | 6691775 | ||
| C0017658 | propylthiouracil | D011441 | 51-52-5 | glomerulonephritis | MESH:D005921 | marker/mechanism | 11250767 | ||
| C0017658 | reserpine | D012110 | 50-55-5 | glomerulonephritis | MESH:D005921 | therapeutic | 11318962 | ||
| C0017658 | rifampin | D012293 | 13292-46-1 | glomerulonephritis | MESH:D005921 | marker/mechanism | 11744817 | ||
| C0017658 | streptozocin | D013311 | 18883-66-4 | glomerulonephritis | MESH:D005921 | marker/mechanism | 19895808 | ||
| C0017658 | sulfadiazine | D013411 | 68-35-9 | glomerulonephritis | MESH:D005921 | marker/mechanism | 3972708 | ||
| C0017658 | troglitazone | C057693 | 97322-87-7 | glomerulonephritis | MESH:D005921 | therapeutic | 11318962 | ||
| C0017658 | valsartan | D000068756 | - | glomerulonephritis | MESH:D005921 | therapeutic | 15315341 | ||
| C0017658 | vancomycin | D014640 | 1404-90-6 | glomerulonephritis | MESH:D005921 | therapeutic | 12680319 | ||
| C0017658 | vitamin e | D014810 | 1406-18-4 | glomerulonephritis | MESH:D005921 | therapeutic | 10353404 | ||
FDA approved drug and dosage information(Total Drugs:8) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D005921 | calcijex | calcitriol | 0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D005921 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D005921 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
| MESH:D005921 | gleevec | imatinib mesylate | EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE;ORAL | Discontinued | None | Yes | No |
| MESH:D005921 | gleevec | imatinib mesylate | EQ 100MG BASE | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D005921 | diovan | valsartan | 80MG | CAPSULE;ORAL | Discontinued | None | No | No |
| MESH:D005921 | diovan | valsartan | 80MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D005921 | afinitor | everolimus | 5MG | TABLET;ORAL | Prescription | None | Yes | No |
FDA labeling changes(Total Drugs:8) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D005921 | 11/16/2001 | calcijex | calcitriol | Management of hypocalcemia in patients undergoing chronic renal dialysis | The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75 | Labeling | B | - | - | - | Abbott | 02/16/2001 | FALSE' |
| MESH:D005921 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D005921 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D005921 | 09/27/2006 | gleevec | imatinib mesylate | Treatment of newly diagnosed pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase | Extended age range for the treatment of newly diagnosed CML down to pediatric patients There are no data in children < 2 years of age Follow-up in children with newly diagnosed Ph+ chronic phase CML is limited Information on hematologic toxicities, AE profile, clinical studies and dosing guidelines new for newly diagnosed pediatric patients | Labeling | - | - | B, P | - | Novartis | 9/6/2006 | FALSE' |
| MESH:D005921 | 09/27/2006 | gleevec | imatinib mesylate | Treatment of newly diagnosed pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase | Extended age range for the treatment of newly diagnosed CML down to pediatric patients There are no data in children < 2 years of age Follow-up in children with newly diagnosed Ph+ chronic phase CML is limited Information on hematologic toxicities, AE profile, clinical studies and dosing guidelines new for newly diagnosed pediatric patients | Labeling | - | - | B, P | - | Novartis | 9/6/2006 | FALSE' |
| MESH:D005921 | 11/29/2007 | diovan | valsartan | Hypertension | Labeling for 6-16 years of age Not recommended for pediatric patients less than 6 years due to safety findings possibly related to treatment or with glomerular filtration rate < 30mL/min/1.73m2 Information on dose, clinical studies in 1-16 years and pharmacokinetics No relevant differences were identified between adverse experience profile for pediatric patients and that previously reported for adult patients Information on preparation of a suspension | Labeling | B | - | - | - | Novartis | 8/8/2007 | FALSE' |
| MESH:D005921 | 11/29/2007 | diovan | valsartan | Hypertension | Labeling for 6-16 years of age Not recommended for pediatric patients less than 6 years due to safety findings possibly related to treatment or with glomerular filtration rate < 30mL/min/1.73m2 Information on dose, clinical studies in 1-16 years and pharmacokinetics No relevant differences were identified between adverse experience profile for pediatric patients and that previously reported for adult patients Information on preparation of a suspension | Labeling | B | - | - | - | Novartis | 8/8/2007 | FALSE' |
| MESH:D005921 | 10/29/2010 | afinitor | everolimus | Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis | Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication | Labeling | B | - | - | - | Novartis | - | FALSE' |